Uterine cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Uterine cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment https://clinicaltrials.eu/trial/a-study-of-cldn6-car-t-cell-therapy-with-or-without-cldn6-rna-lpx-vaccine-in-patients-with-cldn6-positive-advanced-solid-tumors-that-returned-or-did-not-respond-to-treatment/ Wed, 29 Apr 2026 15:08:40 +0000 https://clinicaltrials.eu/trial/a-study-of-cldn6-car-t-cell-therapy-with-or-without-cldn6-rna-lpx-vaccine-in-patients-with-cldn6-positive-advanced-solid-tumors-that-returned-or-did-not-respond-to-treatment/ This study involves patients with solid tumors, which are cancers that form in organs and tissues of the body. The study is examining patients whose cancer has either come back after previous treatment or has not responded to earlier treatments. The treatment being tested is called BNT211, which is a type of cell therapy that uses specially modified immune cells from the patient’s own body. These cells are engineered to recognize and attack cancer cells that have a specific protein called CLDN6 on their surface. In some parts of the study, patients will receive this cell therapy alone, while in other parts, patients will receive the cell therapy together with a vaccine made from genetic material that may help the immune system work better against the cancer.

The purpose of the study is to find out if this treatment is safe and to determine the best dose that patients can tolerate. The study will also look at whether the treatment helps to control or shrink the tumors. Patients in this study must have tumors that show the presence of the CLDN6 protein and must have cancer that has spread or cannot be removed by surgery. The treatment is given through an infusion into a vein. During the study, doctors will closely monitor patients for any side effects and will measure how the tumors respond to the treatment using imaging scans or blood tests that measure certain markers in the blood.

The study will follow patients for several years to understand the long-term effects of the treatment and how well it works over time. Doctors will collect blood samples to measure changes in the immune system and to see how long the modified immune cells stay in the body. The study will test different doses of the cell therapy and the vaccine to find the most appropriate amount to use in future studies. Some patients will receive treatment made using a manual process while others will receive treatment made using an automated process to compare whether both methods work similarly.

]]>